Investors & Media

Corporate Profile

We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, (previously known as TVB-2640), is an oral, once-daily pill in development for the treatment of nonalcoholic steatohepatitis (NASH) that has been studied in over 600 people. It is currently being tested in our FASCINATE-2 Phase 2b trial in NASH. We are also evaluating the promise of FASN inhibition in broader disease areas where dysregulation of fatty acid metabolism plays a key role, including acne and certain forms of cancer.

Data Provided by Refinitiv. Minimum 15 minutes delayed.